LATAM MedTech Insights

In this episode of LATAM MedTech Insights, we demystify the medical device registration process in Peru by taking a close look at the foundational regulation: Supreme Decree Nº 016-2011-SA. We explore how the national authority, DIGEMID, uses a risk-based classification system and what this means for your specific device. We break down the critical requirements that often create barriers for foreign manufacturers, including the mandatory appointment of a Peruvian Registration Holder (PRH) and the specific documentation needed for your submission dossier. This episode provides essential, practical insights for any MedTech company considering Peru as their next market. A Real-World Challenge: Imagine your company has a CE-marked Class III device ready for the LATAM market. You find a distributor in Peru, but your shipment is stopped at customs. Why? Because you didn't appoint a Peruvian Registration Holder (PRH) and your technical dossier wasn't submitted to DIGEMID according to the specific rules of Supreme Decree 016-2011-SA. This episode breaks down how to avoid this costly and time-consuming mistake. What you'll learn in this episode: 1. What is the primary role of Supreme Decree 016-2011-SA in Peru's MedTech landscape? 2. How does Peru's risk classification system (Class I-IV) impact your registration strategy? 3. Why is a Peruvian Registration Holder (PRH) mandatory for all foreign manufacturers? 4. What is a Certificate of Free Sale, and why is it critical for your application to DIGEMID? 5. What are the most common documentation and language pitfalls for companies entering Peru? 6. How long is a Sanitary Registration valid, and what does the renewal process involve? 7. What are the key differences in requirements for low-risk versus high-risk devices? At Pure Global, we specialize in transforming these regulatory hurdles into market opportunities. We offer end-to-end solutions, from acting as your local Peruvian Registration Holder to compiling and submitting your technical dossiers with our advanced AI tools. Stop letting complex regulations slow down your LATAM expansion. Contact us at [email protected] or visit https://pureglobal.com/ to streamline your market access.

In this episode of LATAM MedTech Insights, we provide a detailed analysis of Chile's Resolution Exenta No. 1618/2020, a landmark regulation that established a strict technovigilance framework for medical devices. We dissect the specific reporting obligations, mandatory timelines, and the critical role of the in-country legal representative. This session moves beyond theory to explore the practical challenges and common mistakes foreign manufacturers face when dealing with the Chilean health authority (ISP). We unpack the nuances of identifying trends from seemingly minor incidents and explain how failure to comply can lead to significant regulatory penalties and loss of market access. **What You’ll Learn:** * What is the precise definition of a "reportable adverse event" under Chilean law? * Are you aware of the crucial 10-day vs. 30-day reporting deadlines? * How can a series of minor device malfunctions escalate into a major compliance issue? * Why is your local Chilean representative absolutely essential for successful technovigilance reporting? * What are the most common reporting errors that foreign companies make with the ISP? * How can you differentiate between an isolated incident and a reportable trend? * What are the documentation expectations for an initial adverse event report versus a final one? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us be your local representative and navigate complex regulations for you. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the crucial updates to Brazil's medical device regulations, specifically ANVISA's RDC 497/2021 and the recent amendment RDC 850/2024. We explore how these resolutions have fundamentally changed the administrative process for obtaining and renewing the essential Brazilian Good Manufacturing Practice (B-GMP) certificate. We uncover why the recent extension of B-GMP validity from two to four years makes a flawless submission more critical than ever. We'll walk you through a real-world case study of a diagnostic device manufacturer that faced a three-month market lockout due to minor administrative errors in their renewal application, highlighting the costly pitfalls of navigating these new standardized procedures without expert local knowledge. Key questions answered in this episode: 1. What is the true impact of RDC 497/2021 on my existing Brazilian device registration? 2. How did the recent RDC 850/2024 amendment change the game for B-GMP certificate renewals? 3. What are the most common and costly administrative pitfalls when submitting documents to ANVISA's Solicita system? 4. Why is a simple document codification error now enough to get my entire submission rejected? 5. How far in advance should I begin my B-GMP renewal process to avoid market disruption? 6. What specific steps can I take to ensure my technical dossier is compliant with the latest requirements? 7. How can I turn these regulatory updates into a strategic advantage for my company in Brazil? At Pure Global, we transform regulatory complexity into market access. Our team of local experts, powered by advanced AI tools, offers end-to-end solutions for MedTech and IVD companies in over 30 markets, including Brazil. From initial strategy to post-market surveillance, we act as your local representative to ensure your products reach the market efficiently and remain compliant. Don't let administrative hurdles block your growth in Latin America. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

A response indicating that the requested information could not be found.

This episode of LATAM MedTech Insights offers a detailed guide to registering your medical device in Colombia, focusing on the foundational regulation, Decree 4725 of 2005. We break down the essential requirements set by Colombia's regulatory authority, INVIMA, providing manufacturers with a clear roadmap for successful market entry into one of Latin America's most dynamic healthcare markets. Imagine your company has developed an innovative Class IIb diagnostic device. You are ready to tap into the Colombian market, but your submission is rejected by INVIMA. The reason is a failure to properly appoint a local legal representative and your Instructions for Use (IFU) were not translated into Spanish according to specific regulatory standards. This single oversight delays your launch by over six months, allowing competitors to establish their footprint. This episode provides the details to avoid such costly mistakes. Key Takeaways: 1. What are the four distinct risk classifications for medical devices under Decree 4725 of 2005? 2. Does your product qualify for the faster "automatic registration" pathway in Colombia? 3. Why is a Certificate of Free Sale (CFS) from your device's country of origin an absolute must-have for your INVIMA submission? 4. What are the legal responsibilities of the mandatory in-country representative in Colombia? 5. What are the specific Spanish-language labeling requirements that can lead to an application's rejection? 6. How long is a medical device registration valid in Colombia, and what should you know about the renewal process? 7. What key technical documents are required by INVIMA for a Class IIb or Class III device submission? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market strategy and local representation to AI-powered technical dossier preparation, ensuring your path to the Colombian market is efficient and successful. For expert guidance, contact us at [email protected] or visit us at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the seemingly simple but highly nuanced process of renewing medical device registrations in Argentina. We take a close look at the specific requirements outlined in ANMAT's Disposition 2318/2002, focusing on the critical 90-day submission deadline and the legally binding "sworn declaration." We explore the common pitfalls that can lead to costly delays and even market withdrawal. A minor change in your product's documentation or manufacturing process, considered insignificant in other markets like the EU or USA, could completely invalidate your renewal application in Argentina, forcing you into a lengthy and expensive new registration process. **What You'll Learn:** - What is the absolute deadline for submitting your renewal application to ANMAT, and what are the consequences of missing it? - How does ANMAT's definition of a "significant change" differ from that of the FDA or European Notified Bodies? - Why could a simple update to your Instructions for Use (IFU) derail your entire renewal? - What specific information is included in the "sworn declaration," and what are the legal risks involved? - When is a renewal not an option, forcing you to file for a completely new registration? - What is the critical role of the Authorized Local Representative (ARL) in ensuring a smooth renewal process? Struggling to keep up with the diverse and evolving regulatory requirements across Latin America? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, acting as your local representative in over 30 markets, including Argentina. Let us help you ensure your products remain compliant and accessible. Contact us today at [email protected] or visit https://pureglobal.com/ for a consultation.

This episode of LATAM MedTech Insights provides a detailed analysis of Mexico's mandatory Good Manufacturing Practices (GMP) standard, NOM-241-SSA1-2021. We explore the critical requirements for medical device manufacturers, importers, and distributors operating in Mexico, focusing on the pillars of a compliant Quality Management System (QMS), risk management, and supply chain control. We break down what COFEPRIS, Mexico's health authority, looks for during an audit and why simply being ISO 13485 certified is not enough. This episode is essential for any MedTech company looking to leverage Mexico's manufacturing advantages and access one of the largest markets in Latin America. We also look ahead to the upcoming changes with the 2025 version of the standard, helping you stay ahead of the regulatory curve. Consider this real-world scenario: a U.S. MedTech scale-up invests millions in a state-of-the-art manufacturing facility in Jalisco, aiming to supply the entire LATAM region. However, their market launch is halted after a COFEPRIS audit. The reason? Their risk management files were deemed static, and their supplier validation for a critical component sourced from Asia lacked the specific traceability data required by NOM-241, jeopardizing their entire investment and market-entry strategy. What You'll Learn: 1. Why is NOM-241 a mandatory gateway to the Mexican market and not just a guideline? 2. What are the core pillars of a Quality Management System that COFEPRIS auditors scrutinize? 3. How does NOM-241's approach to technovigilance impact the entire product lifecycle? 4. What are the most common documentation gaps that lead to GMP compliance failures in Mexico? 5. Are your supplier qualification processes robust enough for the standard's strict requirements? 6. How can you prepare your facility for the upcoming changes in the 2025 version of NOM-241? 7. Why might your existing quality certifications be insufficient for gaining approval in Mexico? 8. What specific risk management activities must be continuously updated to maintain compliance? Navigating complex local regulations like NOM-241 is critical for success. At Pure Global, we offer end-to-end regulatory consulting for MedTech companies, combining deep local expertise in over 30 markets with advanced AI tools to streamline your global market access. From initial regulatory strategy to acting as your local representative, we ensure your path to compliance is clear and efficient. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we explore the intricate details of Mexico's medical device labeling standard, NOM-137-SSA1-2008. As one of Latin America's largest MedTech markets, Mexico presents a huge opportunity, but access is strictly controlled by its regulatory body, COFEPRIS. We break down the most common mistakes foreign manufacturers make, from language requirements to the specific data that must be present on your packaging. Learn how to navigate the nuances of primary versus secondary labels, the correct way to use supplementary stickers, and why your local distributor's information is a critical component for avoiding customs delays. Case Study: Imagine your multi-million dollar shipment of medical devices, fully approved in the US and EU, gets stuck indefinitely in Mexican customs. The reason? A single line of missing text on a small sticker. We explore a real-world scenario where a simple labeling mistake involving the distributor's address cost a company months of delays and significant financial loss—a completely avoidable problem. Key questions answered in this episode: 1. Why is simply translating my existing label into Spanish not enough for COFEPRIS?. 2. What specific information about my Mexican distributor must be on the packaging?. 3. How do labeling rules differ for primary sterile packaging versus the outer box?. 4. Can I use stickers to add Mexican requirements, and what are the rules to avoid rejection?. 5. What is a Sanitary Registration number and where must it appear on my label?. 6. Are there upcoming changes to NOM-137 that I need to be aware of right now?. 7. How must the 'Hecho en' (Made in) information be formatted to ensure compliance?. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Let us help you navigate the complexities of markets like Mexico. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we demystify the mandatory INMETRO certification for electro-medical devices in Brazil. We break down the critical requirements of Ordinance 384/2020, a regulation that serves as a vital gatekeeper to one of Latin America's most significant markets. We'll guide you through the conformity assessment process, from selecting a Certification Body to undergoing factory audits and product testing. We explore the distinct roles of ANVISA and INMETRO, clarifying how they work together and what manufacturers must do to satisfy both. We highlight common pitfalls, such as assuming your existing FDA or CE mark documentation is sufficient, and provide actionable insights to ensure a smoother path to certification. This episode is essential listening for any MedTech company planning to sell electro-medical devices in Brazil. A real-world example. A promising European MedTech scale-up developed an innovative portable ultrasound device. They secured CE marking and assumed their technical file was robust enough for global markets. Upon targeting Brazil, they were blocked for months. Their challenge was not the quality of their device, but their failure to understand the nuances of INMETRO's audit process under Ordinance 384/2020, which required specific traceability protocols not emphasized in their EU audit. This oversight led to costly delays and a scramble for local regulatory expertise. Key Takeaways This Episode: 1. What is the fundamental difference between ANVISA's market registration and INMETRO's conformity assessment? 2. How do you select the right INMETRO-accredited Certification Body for your device? 3. What are the three most common documentation mistakes that lead to delays in the certification process? 4. What can you expect during the mandatory on-site factory audit, regardless of your global location? 5. Are INMETRO certificates truly valid indefinitely, and what is the catch? 6. Why is the INMETRO Conformity Identification Seal more than just a label? 7. How can you leverage your Brazil registration strategy for other markets in Latin America? At Pure Global, we transform these complex regulatory hurdles into clear pathways for market access. Our team of local experts, powered by advanced AI and data tools, offers end-to-end solutions for MedTech and IVD companies. From initial regulatory strategy and technical dossier submission to acting as your local representative, we streamline your entry into over 30 global markets, including Brazil. Don't let regulatory complexities be a barrier to your growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.

This episode of LATAM MedTech Insights unpacks the significant changes introduced by Brazil's new medical device regulation, ANVISA RDC 751/2022. We explore how this new framework moves Brazil towards harmonization with international standards, particularly the EU MDR, and what this means for global MedTech companies. We break down the practical impact of the updated risk classification system and the new technical dossier structure. This shift is a game-changer for manufacturers, promising to reduce complexity, time, and cost when entering Latin America's largest market. **Case Study:** Imagine a US-based MedTech scale-up with an innovative patient monitoring system that has already achieved CE marking in Europe. They view Brazil as a critical growth market but are hesitant due to its reputation for complex, unique regulatory requirements. Their primary pain point is the fear of investing months of work and significant capital to completely re-author their technical documentation just for one market. RDC 751 directly solves this by allowing them to leverage their existing EU MDR-compliant dossier, turning a potential roadblock into a streamlined entry point. **Key Takeaways From This Episode:** * How does the new four-tier risk classification system under RDC 751 affect your market entry strategy for Brazil? * What specific sections of your existing EU MDR or FDA technical file can now be repurposed for an ANVISA submission? * Are there changes to the requirements for Brazilian Good Manufacturing Practice (B-GMP) certification? * How does the new regulation impact the need for and the role of a local Brazil Registration Holder? * What are the updated pathways for low-risk versus high-risk devices, and how do they affect your launch timeline? * How will ANVISA's alignment with the IMDRF framework change your future global registration planning? * What are the key considerations for post-market surveillance under the new RDC 751? At Pure Global, we specialize in turning regulatory complexity into market opportunity. With our local expertise in Brazil and advanced AI tools, we offer end-to-end solutions to streamline your ANVISA registration process under RDC 751. Let us be your partner in unlocking the potential of the LATAM market. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

Brazil's MedTech market is one of the largest in Latin America, but its regulatory landscape, governed by ANVISA, can seem complex. Many SaMD companies overestimate the time and difficulty of market entry, missing out on significant opportunities. This episode demystifies the process for Class II Software as a Medical Device. We reveal the streamlined 'notificação' pathway, a simplified notification process that can lead to market approval in as little as 30 days. We walk through a real-world example of a dermatology AI app, detailing how proper preparation of the technical dossier and leveraging local expertise led to a rapid and successful market launch, avoiding common delays that can stall companies for months. What you'll learn in this episode: - What is the difference between ANVISA's 'notificação' and 'registro' pathways? - How can a Class II SaMD be approved in under 30 days in Brazil? - What are the essential documents required for a successful SaMD submission? - Why is a Brazil Registration Holder (BRH) mandatory for foreign companies? - What are the most common mistakes that cause delays in ANVISA's review? - How does regulation RDC 751/2022 impact your device classification? - What specific cybersecurity information does ANVISA expect for a SaMD? At Pure Global, we specialize in transforming complex regulatory challenges into clear, actionable market access strategies. With our end-to-end solutions combining local expertise in over 30 countries and advanced AI tools, we help MedTech and IVD companies accelerate their global expansion. Contact us to streamline your entry into the LATAM market. Email us at [email protected] or visit us at https://pureglobal.com/.

Colombia's MedTech market is one of the fastest-growing in Latin America, offering significant opportunities for global manufacturers. However, navigating its regulatory landscape, managed by INVIMA, presents a unique challenge that can make or break your market entry strategy: the mandatory local legal representative. This episode of LATAM MedTech Insights unpacks this critical requirement. We explore why simply appointing your in-country distributor can be a catastrophic mistake, leading to a loss of control over your own product registration and effectively locking you out of the market. We'll detail the precise role of a legal representative and how choosing an independent partner ensures your business remains agile and in control of its own destiny. Imagine this scenario. You've successfully registered your medical device in Colombia through your distributor. After two years of building the brand, you decide to switch to a new commercial partner for better market penetration. That's when you get the bad news. Your distributor refuses to transfer the registration, which is legally in their name. Your only option is to start the entire expensive and time-consuming registration process from scratch, leaving you unable to sell your product for over a year. In this episode, you will learn the answers to these critical questions: - Why does INVIMA mandate a local representative for all foreign medical device companies? - What are the hidden legal and commercial risks of appointing your distributor as your representative? - How can you permanently lose the rights to your own device registration in Colombia? - What is the crucial difference between a commercial partner and a professional regulatory representative? - What are the key responsibilities a local representative handles beyond just submitting paperwork? - How does an independent representative give you the power to change your sales strategy without regulatory delays? - What specific qualities should you look for when selecting a local representative in Colombia? At Pure Global, we act as your professional, independent legal representative in Colombia and over 30 markets worldwide. We secure your registrations in your name, giving you the freedom to build the best commercial strategy for your products. Don't let a simple mistake lock you out of a key market. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we provide a secure and efficient pathway into Latin America.

In this episode of LATAM MedTech Insights, we explore the essential labeling and language regulations for Software as a Medical Device (SaMD) in Mexico. We unpack the specific requirements set by the national regulatory body, COFEPRIS, and highlight the critical importance of Spanish language localization for a successful market entry. We discuss a common pitfall through a case study: an innovative SaMD company faces a costly six-month delay in their COFEPRIS application. The reason? While all their documents were translated, the software's user interface, including simple menus and error messages, was left in English—a critical oversight that made their product non-compliant. This episode details how to avoid this and other regulatory hurdles. Key questions answered in this episode: - What is the single most important language requirement for medical device software in Mexico? - Which specific Mexican Official Standard (NOM) governs all labeling rules? - Does the language requirement apply to the software's user interface and error messages? - What specific information must be included in the electronic label of a SaMD? - How can a simple localization mistake lead to significant delays and costs with COFEPRIS? - Where must labeling information be placed for software that is downloaded versus distributed on physical media? - Why is treating translation as a final step a major risk for your market access strategy? At Pure Global, we specialize in streamlining global market access for MedTech companies. Our team combines local expertise with advanced AI tools to manage your entire regulatory lifecycle, from initial strategy and technical dossier submission to post-market surveillance. Let us be your local representative in Mexico and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we dissect the complex world of SaMD registration in Brazil. We go beyond the surface-level question of certifications and explore the strategic nuances that can define your success in Latin America's largest market. We explain why simply having an ISO 13485 certificate, the global standard for quality management, is not enough to get your software approved by ANVISA. We uncover the critical role of Brazilian Good Manufacturing Practices (BGMP) and reveal how the Medical Device Single Audit Program (MDSAP) can be your most powerful tool. Learn how leveraging MDSAP can slash your time-to-market from years to months, giving you a significant competitive advantage. Imagine you've developed a groundbreaking AI diagnostic tool. You have your ISO 13485 certificate and are ready to launch in Brazil. You submit to ANVISA, only to be told the wait for a mandatory quality system inspection is over two years long. Your entire commercialization plan is on hold. Meanwhile, your competitor, who also has ISO 13485 but strategically invested in an MDSAP certification, uses it to bypass the inspection queue. They are on the market in six months, capturing key clients while you are still waiting. This episode tells you how to be the competitor who wins. This episode's key takeaways: - Why is an ISO 13485 certificate insufficient for your ANVISA SaMD submission? - What exactly is Brazilian BGMP and which device classes require certification before market entry? - How can the MDSAP program reduce your time-to-market in Brazil by over 18 months? - Are lower-risk SaMD exempt from quality system requirements in Brazil? - What is the difference between a *notificação* and a *registro* pathway for SaMD? - Which specific Brazilian regulation, RDC 657/2022 or RDC 751/2022, governs your software's requirements? - How does a weak regulatory strategy create a two-year competitive disadvantage? At Pure Global, we specialize in turning regulatory hurdles into market opportunities. We offer end-to-end regulatory consulting for MedTech and IVD companies, combining local LATAM expertise with advanced AI tools to streamline your global market access. Let us be your local representative and build the most efficient regulatory pathway for your technology. Contact us at [email protected] or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we demystify the process of registering a foreign-made AI medical device in Mexico. As one of Latin America's largest and most promising markets, Mexico presents a significant opportunity for MedTech innovators. However, its regulatory body, COFEPRIS, has unique requirements that can stall market entry if not navigated correctly. We explore why COFEPRIS treats AI and Software as a Medical Device (SaMD) differently than other global agencies and reveal the single most effective strategy for expedited approval: the Equivalency Agreement. Learn how leveraging your existing FDA, Health Canada, or Japan MHLW clearance can cut your registration timeline in half. We will walk through a real-world case study of a U.S. company that successfully used this pathway, highlighting the critical documents and local requirements they needed to succeed. **This episode's key questions:** - What is the number one mistake foreign companies make when classifying their AI medical device for COFEPRIS? - How can your existing FDA clearance reduce your Mexico market entry timeline from over a year to just a few months? - Why is a Mexican Registration Holder (MRH) legally mandatory before you even submit your application? - What are the specific translation and labeling requirements that COFEPRIS strictly enforces? - How does the risk classification for a software-only device work without a physical component? - What common post-market surveillance duties for AI devices in Mexico often go overlooked? - Are there hidden fees in the COFEPRIS registration process that can surprise foreign applicants? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. If you're looking to enter the complex but rewarding Mexican market, let our experts guide your strategy. Contact us at [email protected] or visit https://pureglobal.com/ for more information.

This episode of LATAM MedTech Insights dives deep into the complex world of clinical data requirements for Software as a Medical Device (SaMD) seeking approval from Brazil's regulatory body, ANVISA. We unpack the critical regulation RDC 657/2022 and explain how ANVISA's risk-based classification system directly dictates the level of clinical evidence your company must provide. We explore the specific pathways for both low-risk and high-risk SaMD. Learn what kind of evidence can be used for simpler devices and understand the rigorous demands for more complex, high-impact software. We highlight common pitfalls and strategic considerations that can make or break your market entry into one of LATAM's most vital healthcare markets. A real-world scenario: Imagine your company has an AI diagnostic tool with successful FDA clearance based on US clinical trials. You're ready to launch in Brazil, but ANVISA puts your application on hold. They are questioning whether your data, collected from a predominantly Caucasian population, is valid for the ethnically diverse population of Brazil. Your launch is now delayed, and you face the unexpected cost of running a local validation study. Key Takeaways: * How does ANVISA's four-tier risk classification for SaMD directly impact your clinical data strategy? * Is your existing clinical data from the US or EU automatically sufficient for a Brazilian submission? * For low-risk SaMD, what are the alternatives to conducting a full clinical trial? * Why might ANVISA challenge world-class clinical data based on patient demographics? * What is a Brazil Registration Holder (BRH), and why is it a non-negotiable requirement for market access? * Under what specific circumstances is a dedicated, local clinical trial absolutely necessary for your SaMD? * How can you effectively leverage data from "equivalent devices" to strengthen your ANVISA submission? * What are the most common documentation and translation mistakes that lead to delays? Navigating the specifics of ANVISA's requirements can be overwhelming. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and technical dossier submission to acting as your official Brazil Registration Holder, we manage the complexities so you can focus on growth. Contact us at [email protected] or visit https://pureglobal.com/ to streamline your market access to Brazil and beyond.

This episode of LATAM MedTech Insights dives into a critical question for innovators: How does Argentina's regulatory authority, ANMAT, handle artificial intelligence and machine learning in medical devices? We cut through the ambiguity to reveal that while there isn't a specific AI-only regulation, these products are actively regulated under the existing robust framework for Software as a Medical Device (SaMD). We explore the practical steps for registering an AI-powered device in Argentina, from the crucial risk classification process to the detailed requirements for your technical dossier. Using the example of an AI tool for diagnostic imaging, we illustrate the challenges and necessities, such as providing extensive algorithm validation data and the mandatory appointment of a local Argentina Registration Holder. This episode provides a clear roadmap for companies looking to enter this key LATAM market with cutting-edge technology. Key Takeaways: * What is the current official stance of ANMAT on regulating AI-specific medical devices? * How does Argentina's four-tier risk classification system apply to Software as a Medical Device? * What are the essential components of a technical dossier for an AI algorithm submitted to ANMAT? * Why is appointing an Argentina Registration Holder a non-negotiable step for foreign manufacturers? * What is the role of the IMDRF in shaping the future of AI medical device regulation in Argentina? * How can you prove the safety and efficacy of a "black box" machine learning algorithm to regulators? * What are the most common pitfalls to avoid when submitting an advanced software device for approval in Argentina? At Pure Global, we specialize in demystifying complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI tools to streamline your global market access. Let us be your local representative and strategic partner in Latin America and beyond. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

As Colombia's healthcare market embraces digital transformation, understanding the regulatory pathway for Software as a Medical Device (SaMD) is crucial for innovators. This episode of LATAM MedTech Insights demystifies the INVIMA registration process, revealing that SaMD is not regulated under a separate framework, but through the country's existing medical device decrees. We provide a clear, step-by-step guide for manufacturers looking to enter this promising market. We break down the essential requirements, from the critical first step of risk classification to the mandatory appointment of a local legal representative. We detail the specific documentation needed for your technical dossier, including software validation, cybersecurity measures, and the crucial Certificate of Free Sale. Learn why a simple translation of your documents isn't enough and how to avoid the common pitfalls that can lead to significant delays and rejections from INVIMA. A US-based startup with an FDA-cleared AI diagnostic tool learned this the hard way. They assumed their existing documentation would suffice for their INVIMA submission but faced a nine-month delay. The reason? Their risk analysis failed to address specific patient data privacy concerns relevant to Colombian law, and their software validation data was presented in a format that was unfamiliar to the INVIMA reviewer, leading to a cascade of questions they were unprepared to answer. This costly delay could have been avoided with localized regulatory expertise. What You'll Learn: 1. Why is there no dedicated "SaMD" regulation in Colombia, and what does that mean for your submission? 2. What is the single most important decision you'll make before starting your INVIMA application? 3. Do you need a physical office in Colombia to register your software device? 4. How crucial is a Certificate of Free Sale from your home country for the approval process? 5. What specific software validation documents does INVIMA expect to see in your technical file? 6. Beyond simple translation, what localization details are critical for your labeling and instructions for use? 7. What is the most common and costly mistake that leads to long delays in the INVIMA review process? 8. How do cybersecurity considerations play a role in the Colombian registration of SaMD? At Pure Global, we specialize in transforming these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise in over 30 markets with advanced AI and data tools to streamline your global expansion. From initial strategy to post-market surveillance, our team acts as your local representative to ensure your innovation reaches the market efficiently. Contact us to learn more at [email protected] or visit our website at https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore the significant regulatory shift in Mexico concerning AI-powered medical software. Mexico's health authority, COFEPRIS, has updated its framework, moving away from treating software as a simple accessory to classifying it as a regulated medical device in its own right. This change is crucial for any MedTech company aiming to penetrate the vibrant Mexican market. We break down the new risk-based classification system—Class I, II, and III—and discuss how the intended use of your AI software determines its regulatory pathway. This episode provides essential information for developers and manufacturers, ensuring they understand the new rules of engagement to avoid costly delays and rejections. Case Study Spotlight: Imagine spending years developing a revolutionary AI tool that predicts cardiac risk from a selfie, only to have your market entry blocked by regulatory confusion. We examine the success story of Medsi AI, a company that successfully navigated the new COFEPRIS guidelines to get their AI-powered diagnostic platform approved as a Class II medical device, setting a vital precedent for the industry. Key Takeaways: - Why did COFEPRIS fundamentally change its regulations for Software as a Medical Device (SaMD)? - What are the specific criteria for Class I, II, and III risk classifications in Mexico? - How does my AI software's intended use directly impact its classification and submission requirements? - What key documentation was crucial for Medsi AI to secure its Class II approval? - Can I leverage my existing FDA or CE marking for an expedited review with COFEPRIS? - What are the most common pitfalls to avoid when submitting an AI SaMD application in Mexico? - How will this regulatory shift impact the future of digital health innovation in Latin America? Navigating the complex regulatory landscape of Latin America is our expertise. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline your global market access. For a clear and efficient pathway into markets like Mexico, contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we demystify the regulatory maze of Brazil's ANVISA for companies developing AI and Software as a Medical Device (SaMD). As the largest market in Latin America, Brazil presents a massive opportunity, but its regulatory agency, ANVISA, has specific and stringent requirements that can stall market entry if you're unprepared. We explore the cornerstone regulation, RDC 657/2022, and how it interacts with the broader medical device framework. We break down the crucial four-tier risk classification system and explain how it dictates your entire path to market, from a simple notification for low-risk software to a full, complex registration for high-risk AI-driven diagnostics. Imagine your AI diagnostic tool, already successful in Europe with a CE mark, is ready for the Brazilian market. You begin the process, only to be stalled for months by unexpected demands for algorithm validation data, cybersecurity protocols, and the non-negotiable requirement for a local Brazil Registration Holder. This common pitfall can cost you valuable time, resources, and your first-mover advantage in a competitive landscape. Key Questions from this Episode: - What is the single most important ANVISA regulation you must know for SaMD in Brazil? - How does ANVISA classify the risk of your AI-powered medical software, and why is this the most critical step? - Does your low-risk SaMD need a full registration (*registro*) or a simpler notification (*notificação*)? - What specific documentation is required for high-risk AI devices that differs from traditional hardware? - Why is a Brazil Registration Holder (BRH) an absolute necessity for market entry? - How does ANVISA scrutinize the datasets used to train your machine learning algorithms? - What are ANVISA's expectations for post-market surveillance of adaptive AI that learns over time? - Can you leverage existing international approvals like a CE mark or FDA clearance to speed up your Brazilian submission? At Pure Global, we specialize in transforming these regulatory hurdles into strategic advantages. We offer end-to-end solutions, from developing your ANVISA submission strategy and compiling technical dossiers to acting as your local Brazil Registration Holder. Our blend of local expertise and advanced AI tools streamlines your path to market access across Latin America. Don't let regulatory complexity be a barrier to entry. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your growth.

This episode of LATAM MedTech Insights tackles a critical question for manufacturers entering Brazil: Is a Good Manufacturing Practice (GMP) certificate really required for low-risk, Class I medical devices? We explore the common misconceptions surrounding ANVISA's RDC 751/2022 regulation and the simplified *notificação* registration pathway. Many companies assume the lack of an upfront certificate submission means compliance is optional. This can be a costly mistake. We reveal how ANVISA's post-market surveillance can place your market access at risk if you're not prepared, and discuss how programs like MDSAP can be a strategic asset for demonstrating compliance. **A Case Study in Risk:** Imagine your startup's Class I device is successfully launched in Brazil via the "easy" *notificação* route. Six months later, ANVISA announces a surprise inspection of your facility. Are you confident your Quality Management System is fully B-GMP compliant right now? If not, you face immediate product withdrawal, fines, and reputational damage. This episode tells you how to avoid that scenario. **Key Takeaways From This Episode:** - Do all device classes truly need a B-GMP certificate before registering in Brazil? - What is the crucial difference between compliance and submission under RDC 751/2022? - Why can the simplified *notificação* pathway for Class I devices become a regulatory trap? - How can a post-market surveillance audit jeopardize your entire Brazilian market presence? - What is the one program that can significantly streamline your ANVISA compliance process? - Is your Quality Management System truly ready for an unannounced ANVISA inspection today? - What is the real role of the Medical Device Single Audit Program (MDSAP) in Brazil? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop regulatory strategy, and ensure ongoing compliance in over 30 markets, including Brazil. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your market access.

This episode of LATAM MedTech Insights dives deep into the often-underestimated challenge of labeling requirements for low-risk medical devices in Latin America. We uncover the fragmented regulatory landscape and reveal why a one-size-fits-all approach is doomed to fail. We explore the specific, nuanced requirements of key markets including Brazil (ANVISA), Mexico (COFEPRIS), Colombia (INVIMA), and Argentina (ANMAT), moving beyond simple language translation to discuss the critical data points that regulators are looking for. Imagine this scenario. A promising European startup ships its innovative Class I diagnostic device to Colombia. They've secured the "automatic" INVIMA registration and applied a Spanish-language sticker over their original CE-marked packaging. However, the shipment is seized by customs. The reason? The sticker, while translated correctly, failed to include the full name and address of their appointed Colombian importer and the specific INVIMA registration number. This small oversight leads to weeks of delays, costly storage fees, and a frantic effort to relabel the entire shipment, jeopardizing a critical product launch and damaging their relationship with their new distributor. This week's key takeaways: - Why does Brazil's ANVISA require more than just a Portuguese translation on your Class I device label? - What is the single most common labeling error that leads to customs detentions in Mexico? - For Colombia's "automatic" registration, what specific information must be on the label to avoid rejection? - Can you ever omit the Instructions for Use for a low-risk device in Argentina? - How do requirements for importer information differ between ANMAT and COFEPRIS? - What are the risks of assuming your FDA or CE-compliant label is "good enough" for LATAM? - Why can the labeling of individual components within a kit create a major compliance headache? - How can you manage label updates efficiently across multiple Latin American countries? Struggling to keep up with the diverse and ever-changing labeling rules across Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local, in-country expertise with advanced AI and data tools to streamline your global market access and ensure your products, including their labels, are fully compliant. Stop letting small details cause big problems. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This episode of LATAM MedTech Insights dives into a critical, often misunderstood, aspect of entering the Brazilian market: the requirement of a Brazil Registration Holder (BRH) for low-risk, Class I medical devices. While these devices follow a simplified "notificação" process instead of a full registration, foreign manufacturers are still legally required to have a local entity representing them before the regulatory body, ANVISA. We explore why this requirement exists and the significant risks of appointing a commercial distributor as your BRH. This common mistake can lead to a loss of market access, create conflicts of interest, and severely limit your company's commercial flexibility and growth within Latin America's largest MedTech market. A US-based startup learned this the hard way. They developed a Class I software-as-a-medical-device and, believing the "low-risk" classification meant a simple process, allowed their first Brazilian distributor to become their BRH. When the partnership soured due to poor performance, the startup was shocked to find they couldn't simply switch distributors. The original partner owned the ANVISA registration and refused to transfer it, demanding a hefty buyout. The startup was trapped, unable to sell their product through any other channel, effectively halting their Brazilian expansion for 18 months until the issue was legally resolved. Key Questions from this Episode: 1. Why is a Brazil Registration Holder mandatory even for low-risk devices that only require a simple notification? 2. What are the hidden dangers of letting your distributor "own" your product registration with ANVISA? 3. How can the wrong BRH choice legally block you from working with other sales partners in Brazil? 4. What is the precise legal role of a BRH in post-market surveillance and incident reporting? 5. Is it possible to transfer your registration from one BRH to another, and what challenges might you face? 6. How does an independent BRH provide the flexibility needed to scale your business across Brazil? 7. What are the key differences between the 'notificação' and the 'registro' pathways at ANVISA? At Pure Global, we offer end-to-end regulatory consulting solutions, serving as your independent, professional Brazil Registration Holder. We combine local expertise with advanced AI and data tools to streamline your market access while giving you complete control over your commercial strategy. Decouple your regulatory compliance from your distribution network and secure your access to the Brazilian market. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode of LATAM MedTech Insights, we demystify the "automatic" registration process for low-risk medical devices in Colombia. We explore the requirements set by the national regulatory body, INVIMA, for Class I and IIa devices, detailing the specific documentation needed for a successful and speedy market entry. We break down why this streamlined pathway is a major advantage for MedTech manufacturers targeting the Colombian market. Learn how to leverage your existing approvals and what common administrative errors can cause significant delays, turning a fast-track process into a frustrating roadblock. Consider the case of a scale-up company with an innovative Class IIa device. They targeted Colombia for its efficient "automatic" registration, hoping for a quick launch. However, their submission was rejected. The reason was a simple administrative oversight: their translations were not officially certified and their home country approval lacked the required Apostille. This small error cost them an entire quarter of lost sales and market momentum, a painful lesson in the importance of local regulatory details. What You'll Learn: 1. What does INVIMA's "automatic" registration for low-risk devices really mean? 2. Which specific device classes are eligible for this streamlined process in Colombia? 3. What is the single most critical document you need from your home country to even begin? 4. Why can a simple mistake in document legalization derail your entire submission? 5. How can you ensure your Spanish translations meet INVIMA's strict requirements? 6. What are the key components of the technical dossier required for a Class I or IIa device? 7. How quickly can you start selling in Colombia after a successful submission? 8. What is the role of a local representative in this notification process? At Pure Global, we specialize in transforming these complex regulatory hurdles into clear pathways for market access. Our end-to-end solutions, combining local LATAM expertise with advanced AI tools, ensure your submission is right the first time. Stop letting paperwork stand in the way of your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your entry into over 30 global markets.

Entering Argentina's lucrative MedTech market presents a huge opportunity, but it's filled with regulatory complexities. A common and costly mistake manufacturers make is assuming that low-risk, Class I medical devices are exempt from registration with the national authority, ANMAT. This single misunderstanding can lead to product seizures at customs, unexpected costs, and a complete halt to your market entry strategy. In this episode, we uncover the truth behind this myth. We explore a real-world case of a surgical instrument company whose first major shipment was impounded at the border. They faced mounting demurrage charges and a frantic search for a solution, all because they lacked the mandatory registration for their "simple" Class I device. This story highlights the critical difference between a streamlined process and a non-existent one, and the essential role of a local registration holder. Key Takeaways: - Why is "exemption" a dangerous myth for any medical device class in Argentina? - What is ANMAT's four-tier classification system and how does it determine your registration pathway? - What specific steps and documents are required for the 'simplified' registration for Class I devices? - What is the HELENA system and who is authorized to use it for submissions? - Why should your Argentina Registration Holder (ARH) be independent from your distributor? - What happens to your market access if your relationship with your distributor-ARH ends? - How can you prevent your product from being detained by Argentinean customs? At Pure Global, we provide the local expertise and end-to-end regulatory solutions to navigate these challenges. We act as your independent Argentina Registration Holder, securing your market access and ensuring your business continuity. Don't let regulatory myths derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can streamline your entry into Latin America.

In this episode of LATAM MedTech Insights, we demystify the process of registering a low-risk (Class I) medical device in Mexico. Don't let the "low-risk" classification fool you; navigating the requirements of COFEPRIS, Mexico's health authority, is a complex journey filled with potential pitfalls that can delay your market entry indefinitely. We break down the essential steps, from appointing a legally required Mexico Registration Holder (MRH) to compiling a flawless technical dossier. We uncover the most common mistakes foreign manufacturers make, such as improper document legalization and translation errors, which lead to costly rejections and wasted time. This episode is a must-listen for any MedTech company looking to tap into the lucrative Mexican market efficiently and successfully. **Case Study Highlight:** Imagine a US-based scaleup with an innovative Class I diagnostic tool. They've secured a major distributor in Mexico City, but their launch is stalled for over eight months. Why? Their technical dossier, perfectly valid for the FDA, was rejected twice by COFEPRIS due to improper Spanish translations and missing apostilles on their legal documents. This failure cost them crucial first-mover advantage and strained vital partner relations, a scenario that is all too common and entirely avoidable. **Key Questions Answered (本期干货):** * Why is a 'low-risk' classification from COFEPRIS not the same as a 'no-paperwork' registration? * What is the single most critical role of a Mexico Registration Holder, and how can choosing the wrong one jeopardize your business? * What is an apostille, and why could its absence on your documents lead to an instant rejection from COFEPRIS? * Are standard translation services sufficient for your technical dossier, or do you need a specific type of translator to be successful? * Can you really leverage your FDA 510(k) to speed up COFEPRIS approval, and what are the hidden catches? * What specific document in your dossier is most often submitted incorrectly by foreign companies? * How does the COFEPRIS Equivalency Agreement actually work, and is your device eligible? At Pure Global, we transform these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative in over 30 markets, including Mexico. Our blend of local expertise and advanced AI tools streamlines the registration process, saving you time and money. Stop letting regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to get started.

This episode of LATAM MedTech Insights tackles the common misconceptions surrounding the registration of Class I medical devices in Brazil. We move beyond the outdated term "cadastro" to provide a detailed breakdown of the current "notificação" (notification) pathway managed by ANVISA. Learn why this simplified, faster route to market is often misunderstood by foreign manufacturers. We explore the critical, non-negotiable requirements that are often overlooked. From the strategic importance of selecting the right Brazil Registration Holder (BRH) to the necessity of a complete technical dossier that ANVISA can audit at any time, we cover the essential groundwork. We share a real-world example of a company whose product launch was delayed for months simply because their translated user manual didn't meet specific Brazilian formatting rules, highlighting how a small oversight can lead to significant commercial setbacks. This episode is a must-listen for any MedTech company looking to successfully enter the lucrative Brazilian market. Key Takeaways: * What is the crucial difference between the "cadastro" and the modern "notificação" process? * Why is your choice of a Brazil Registration Holder (BRH) the single most important decision for your market entry strategy? * Does a "simplified notification" mean you don't need a full technical dossier? * What are the specific labeling and language requirements that cause the most customs delays? * How do you determine if your Class I device needs a separate INMETRO certification? * What post-market surveillance responsibilities fall on your BRH? * Why is assuming "low-risk" means "low-compliance" a major financial risk in Brazil? At Pure Global, we specialize in transforming these regulatory hurdles into clear pathways for market success. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and ensuring full compliance across Latin America and more than 30 markets worldwide. Let us handle the complexities of ANVISA, so you can focus on growth. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

Many MedTech companies dream of a single registration process for the entire Mercosur market, including giants like Brazil and Argentina. Is this a reality, or just a regulatory myth? This episode of LATAM MedTech Insights dives deep into the current state of regulatory harmonization in the region. We uncover the practical challenges and strategic opportunities that exist today. While Mercosur is moving towards a unified framework, the reality on the ground is a complex patchwork of national adoptions and lingering local requirements. We break down why you can't use a single dossier and what this means for your market access strategy, timelines, and budget. **Key Questions Answered in this Episode:** * Is there truly a single registration dossier for all of Mercosur? * How does Brazil's ANVISA registration differ from Argentina's ANMAT, even under new Mercosur rules? * What is the most significant non-tariff barrier to entry in Brazil for medical devices? * Which specific GMC resolution is changing the game for MedTech in the region? * Why is a local, in-country representative still non-negotiable in each market? * How are countries like Uruguay and Paraguay adopting these harmonized standards? * What are the common pitfalls that delay product launches in LATAM? * How can you leverage one country's approval to potentially speed up the process in another? At Pure Global, we specialize in turning these complex regulatory challenges into clear market access strategies. Our team offers end-to-end solutions, from acting as your local representative in Brazil and Argentina to compiling technical dossiers with AI-powered efficiency. Don't let regulatory hurdles slow your growth in LATAM. Contact us for a consultation at [email protected] or visit https://pureglobal.com/ to learn more.

Colombia is one of Latin America's most promising MedTech markets, but gaining access requires navigating the complex regulatory landscape of its authority, INVIMA. While official timelines suggest a straightforward process, the reality on the ground can be quite different, with unexpected delays impacting launch plans and revenue forecasts. In this episode, we uncover the real-world timelines for medical device registration in Colombia. We explore a case study of a European orthopedic company that planned for an 8-month approval for their Class IIb device, only to be delayed by an additional five months due to a request for information regarding the applicability of their clinical data, costing them significant time and market opportunity. Key Takeaways: * What are INVIMA's official review timelines for different device classes? * Is there a fast-track 'automatic' registration process for certain devices? * Why do official timelines often not match reality in Colombia? * What is the single most common reason for significant registration delays? * How does a request for additional information (RFI) impact your approval clock? * Are there specific Spanish language requirements for technical dossiers that companies often miss? * How does your existing FDA or CE Mark approval impact your submission to INVIMA? * Why is having a local legal representative a non-negotiable first step? At Pure Global, we specialize in transforming these regulatory challenges into market opportunities. With our local expertise in Colombia and advanced AI tools, we streamline the INVIMA registration process, helping you avoid common pitfalls and accelerate your market access. Contact us to learn how we can help you at [email protected] or visit https://pureglobal.com/.

Entering the Brazilian MedTech market is a massive opportunity, but it comes with a critical gatekeeper: the ANVISA Brazilian Good Manufacturing Practice, or BGMP, inspection. This episode of LATAM MedTech Insights demystifies this complex process for foreign manufacturers. We break down the step-by-step journey, from the initial application submitted by your Brazil Registration Holder to the intense, on-the-ground audit by ANVISA inspectors. We explore the nuances that go beyond standard ISO or MDSAP certifications and delve into the specific expectations of Brazilian regulators. This is your essential guide to understanding what it truly takes to get your manufacturing site approved for one of Latin America's most lucrative healthcare markets. Consider this common scenario: A U.S.-based device company, fully MDSAP certified, waited 18 months for their ANVISA inspection. They believed they were perfectly prepared, but the audit resulted in a critical non-conformity. Why? The inspectors discovered a subtle gap in their post-market surveillance data collection process that didn't align with Brazil's specific reporting requirements. This oversight led to a costly six-month delay and a complete re-submission, a frustrating setback that local expertise could have prevented. Key questions answered in this episode: 1. Why is your choice of a Brazil Registration Holder the most critical first step? 2. What are the three key documents ANVISA will scrutinize before they even schedule your visit? 3. How does an MDSAP audit differ from what a Brazilian inspector looks for on your factory floor? 4. What is the single most common reason foreign manufacturers fail their first BGMP inspection? 5. How can you prepare your shop-floor team for the detailed questions they will face? 6. What are ANVISA's expectations for traceability records, from raw material to finished device? 7. Are there new risk-based approaches that could help you bypass a physical inspection? At Pure Global, we specialize in turning these regulatory hurdles into market access pathways. We offer end-to-end regulatory consulting, acting as your local representative and leveraging AI-driven tools to ensure your submission is flawless. Don't navigate the complexities of ANVISA alone. Contact us for a strategic consultation at [email protected] or learn more by visiting https://pureglobal.com/.

This episode of LATAM MedTech Insights dives deep into the real costs of registering a medical device in Peru. We uncover why the official DIGEMID government fees are just the tip of the iceberg and explore the significant hidden expenses in local representation, technical dossier translation, and costly time delays that can derail your market entry strategy. We break down the critical strategic decision of appointing a Peru Registration Holder (PRH). Imagine a medical device scaleup, excited to enter the Peruvian market. They budget for the official fees but are blindsided when their registration is tied to a single distributor who holds their market access hostage. This common pitfall prevents them from expanding their commercial network and costs them a year in lost revenue to fix. This episode teaches you how to avoid this and other costly mistakes. Key Takeaways: * Why are official government fees only 10% of your total registration cost in Peru? * What is a Peru Registration Holder (PRH), and why is choosing the wrong one a critical strategic mistake? * How can simple Spanish translation errors lead to a complete dossier rejection by DIGEMID? * What are the hidden operational costs associated with preparing a technical file for the Peruvian market? * How can you leverage existing approvals like an FDA 510(k) or a CE Mark to potentially speed up your process? * What is the true opportunity cost of a 12-month registration delay, and how can you mitigate it? * Why is an independent local representative often a better long-term investment than your distributor? At Pure Global, we provide end-to-end regulatory consulting to help MedTech companies navigate complex markets like Peru. Our integrated approach combines local, in-country expertise with advanced AI tools to streamline dossier preparation, manage submissions, and act as your independent local representative. We turn regulatory hurdles into market opportunities. To secure and accelerate your market access in Latin America, contact us at [email protected] or visit https://pureglobal.com/.

Many MedTech innovators see their FDA approval or CE mark as a golden ticket to Latin America, often targeting Chile first due to its reputation as an accessible market. However, the ground rules are changing fast. What was once a largely voluntary system is now shifting to a mandatory registration framework for all medical devices, creating new hurdles for unprepared companies. This episode of LATAM MedTech Insights dives into the reality of entering the Chilean market today. We uncover why your existing certifications are not a direct passport for sales but are the critical foundation for a successful regulatory submission to Chile's health authority, the ISP. What you'll learn in this episode: - Why was Chile historically considered an "easy" market in LATAM, and why is this no longer true? - Is registration with the ISP now mandatory for all medical devices? - Can I sell my device directly in Chile if it has FDA 510(k) clearance? - What is the role of a Certificate of Free Sale (CFS) in the Chilean registration process? - How does the ISP review technical dossiers based on CE marking or FDA approval? - What are the biggest mistakes companies make when entering the Chilean MedTech market? - Do I need a local legal representative or registration holder in Chile? - How long does the registration process typically take for a device with prior CE/FDA approval? Navigating the nuances of market access in Chile and across Latin America requires local expertise and a strategic approach. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline global market access. Let us help you turn your existing approvals into successful registrations. Contact us at [email protected] or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we explore the non-negotiable Spanish labeling requirements for medical devices in Colombia. We delve into INVIMA's regulations under Decree 4725 and explain why simply having FDA or CE approval isn't enough to guarantee a smooth market entry. We’ll walk through a real-world case study of a US company whose launch was delayed by six months due to overlooked translation of their device's software and manual. This costly mistake highlights the critical importance of a localized approach and the severe commercial impact of non-compliance. Learn what "labeling" truly covers and how to avoid common pitfalls. Key Questions Answered in This Episode: - What specific Colombian decree mandates Spanish for medical device labels? - Does "labeling" include just the box, or also the software and user manual? - Can I use a simple sticker with Spanish translation over my original English label? - What are the real business costs of getting the language requirement wrong in Colombia? - Why is a direct machine translation of my IFU a high-risk strategy? - How early in my product development should I plan for multi-language labeling? - What's the best practice for designing packaging for both US and Colombian markets? At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end solutions, from local representation to AI-powered technical dossier preparation, ensuring your MedTech and IVD products meet all local requirements in over 30 countries. Don't let language be a barrier to your success. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.

In this episode of LATAM MedTech Insights, we dive into one of the most critical and often misunderstood aspects of entering the Argentine medical device market: the role of the local registration holder. While ANMAT's requirement for a local representative seems straightforward, the legal implications of who you choose can have massive consequences for your business. We explore why appointing your commercial distributor as your registration holder can be a high-risk strategy. This episode uncovers how this common practice can lead to a complete loss of market access, forcing companies to restart the costly and time-consuming registration process from zero. We detail the strategic advantages of separating your regulatory representation from your commercial partnerships to ensure business continuity and protect your investment. **What You'll Learn:** - Why is ANMAT's requirement for a local registration holder more than just an administrative step? - What are the hidden risks of appointing your distributor as your registration holder in Argentina? - Who legally owns your medical device registration in Argentina, and why does it matter? - If you split with your local partner, what happens to your hard-won market approval? - How can an independent representative provide business continuity and control over your assets? - Is this registration ownership model unique to Argentina, or is it a common theme in LATAM? - What key criteria should you use when selecting a local registration holder in Argentina? At Pure Global, we specialize in providing independent, expert local representation to safeguard your market access. We act as your registration holder across Latin America, ensuring you maintain full control over your assets while having the flexibility to build the best commercial strategy. Ready to secure and streamline your entry into Argentina? Contact us at [email protected] or visit https://pureglobal.com/ for a strategic consultation.

In this episode of LATAM MedTech Insights, we demystify the complex web of medical device classification rules across Latin America's key markets. While most countries use a risk-based system, the specific requirements of agencies like Brazil's ANVISA, Mexico's COFEPRIS, and Colombia's INVIMA present unique challenges that can derail market entry for unprepared companies. We explore how seemingly minor details in documentation, translation, and local procedural norms can lead to major delays. This episode provides essential insights for any MedTech company looking to expand into this dynamic but demanding region, moving beyond the regulations to discuss real-world examples and common pitfalls. For example, consider a European MedTech company with a CE-marked Class IIa device. They targeted Colombia, assuming a smooth registration process due to the similar classification system. However, they faced a six-month delay because their technical dossier, while compliant in the EU, lacked specific local declarations and formatting required by INVIMA. This small oversight cost them a critical sales season and highlighted the importance of localized expertise. Key questions answered in this episode: - Why isn't there a single classification system for all of Latin America? - What's the crucial difference between Brazil's `Cadastro` and `Registro` pathways? - How can a reference country approval from the FDA help in Mexico, and what is the most common mistake companies make in the process? - Why does Colombia's EU-like system still catch experienced European manufacturers by surprise? - What are the top three documentation details that lead to registration rejection in these key markets? - How do device grouping or family definitions differ between ANVISA, COFEPRIS, and INVIMA? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. Our combination of local experts in over 30 markets and advanced AI-powered data tools ensures your path to registration is clear and efficient. Don't let regulatory details derail your LATAM expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your market access.

This episode of LATAM MedTech Insights dives deep into the medical device approval process in Mexico, governed by the regulatory body COFEPRIS. We demystify the requirements, from device classification to the critical role of a local registration holder, providing a clear roadmap for international MedTech companies looking to enter this lucrative market. We explore the strategic pathways that can save you valuable time and resources. Discover how leveraging your existing approvals from bodies like the US FDA or Health Canada can dramatically accelerate your journey to market, transforming a potentially lengthy process into a streamlined and predictable one. A US-based scaleup with a novel Class II device faced this exact scenario. Their initial submission was stalled for over a year due to documentation errors and a lack of a clear strategy, costing them valuable time and market opportunity. This episode reveals how leveraging an often-overlooked equivalency pathway could have cut their approval time in half and avoided costly mistakes. Key Takeaways from this episode: 1. What are the four main risk classifications for medical devices in Mexico? 2. How can you use your existing FDA or Health Canada approval to speed up COFEPRIS registration? 3. What is a Mexican Registration Holder (MRH), and why is choosing the right one critical to your business's future? 4. What common documentation mistakes lead to costly delays with COFEPRIS? 5. How does the new "Abbreviated Pathway" coming in 2025 change the game for manufacturers? 6. Is it better to use your distributor as your MRH, or an independent third party? 7. What are the specific post-market surveillance requirements you must meet in Mexico? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, including Mexico, to get your product approved and maintain compliance. Contact us to learn how we can accelerate your entry into the LATAM market at [email protected] or visit us at https://pureglobal.com/.

Brazil's MedTech market is a massive opportunity, but ANVISA's complex and unique regulatory requirements can be a significant barrier for foreign manufacturers. This episode provides a clear, step-by-step guide to navigating the medical device registration process, breaking down everything from initial classification to post-market responsibilities. We uncover the critical decisions and common pitfalls that can delay your market entry by years and cost you millions. Learn the strategic importance of every step, from selecting a local partner to preparing for rigorous facility audits, and discover how to leverage recent regulatory changes to your advantage. **Featured Case:** Imagine spending two years and hundreds of thousands of dollars to get your innovative medical device approved in Brazil, only to realize your distributor legally owns your registration. When you decide to switch to a better partner, you're forced to start the entire lengthy and expensive process all over again. This episode explains how this common and costly trap occurs and provides a clear strategy to avoid it from day one. **Key Questions Answered:** - Why is choosing your Brazil Registration Holder (BRH) the single most critical decision for market access? - What is the difference between a Cadastro and a Registro submission, and which path does your device need to follow? - Can my existing FDA clearance or CE Mark help fast-track my ANVISA application? - What specific preparations are needed to pass the mandatory Brazilian Good Manufacturing Practice (BGMP) audit? - Is it possible for a foreign company to register a device without a physical office in Brazil? - How do you avoid the common pitfall of losing your device registration when you change local distributors? - What are the latest regulatory updates from ANVISA that can accelerate your approval timeline? - Why must all technical documentation be submitted in Brazilian Portuguese, and what's the best way to manage this? At Pure Global, we offer end-to-end regulatory solutions to streamline your global market access. We act as your independent local representative in Brazil and over 30 other markets, ensuring you always maintain full control of your assets. Our team combines local expertise with advanced AI tools to efficiently manage technical dossiers, navigate complex submissions, and monitor regulatory changes. Don’t let regulatory hurdles block your entry into LATAM's most promising market. Contact us today at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your path to market.

Brazil represents the largest MedTech market in Latin America, but its regulatory landscape, governed by the agency ANVISA, is one of the most demanding in the world. This episode breaks down the essential steps and common pitfalls companies face when seeking medical device approval in this complex market. We provide a clear overview of the multi-layered process, from initial facility certification to final product registration.We explore the critical requirements that every MedTech manufacturer must meet, including the often-underestimated B-GMP certification, the different registration pathways based on device risk class, and the strategic importance of selecting the right Brazil Registration Holder (BRH). We also share a crucial real-world example: learn about a company that appointed its distributor as its BRH, only to find itself trapped and unable to change commercial partners without losing its hard-won market registration, forcing a complete restart of the entire process.This episode's key takeaways:- Why is a B-GMP certificate the first, and often biggest, hurdle to clear before even submitting your device dossier?- What is the crucial difference between the 'Notificação' and 'Registro' pathways under the new RDC 751/2022 regulation?- Why is choosing your Brazil Registration Holder one of the most critical strategic decisions you will make?- What common mistake can lead to a complete loss of control over your product's registration in Brazil?- How do you prepare a technical dossier that meets ANVISA’s specific and demanding requirements?- Do you need additional certifications like INMETRO or ANATEL for your device?- How can you avoid years of delays and unexpected costs when entering the Brazilian market?Navigating the complexities of the Brazilian market requires local expertise and a robust regulatory strategy. At Pure Global, we offer end-to-end solutions, acting as your local representative and using advanced tools to streamline dossier submissions. Ready to build your LATAM market access strategy? Contact our experts at [email protected] or visit https://pureglobal.com/.